University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center
You need to answer all questions correctly to earn continuing medical education credit.
a. Improved response rates
b. Reduced side effects
c. Increased pill burden
d. Increased viral resistance
a. Pegylated interferon/ribavirin 4-week lead-in phase
b. Increased absorption of telaprevir when taken with a fatty meal
c. Administration of telaprevir for 24 weeks
d. Dysgeusia occurs in about one third of patients
HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2013, Regents of the University of California.